KalVista CDO logs RSU vest and tax share sale

KalVista Pharmaceuticals chief development officer Christopher Yea reported RSU vesting and related share activity.

Rhea-AI Filing Summary

KalVista Pharmaceuticals chief development officer Christopher Yea reported RSU vesting and related share activity. On February 17, 2026, 1,774 restricted stock units were converted into 1,774 shares of common stock for no cash consideration. On February 18, 2026, 1,109 common shares were sold at $15.00 per share solely to cover tax withholding obligations under a pre-arranged “sell to cover” and were not a discretionary sale.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Yea Christopher

Role CHIEF DEVELOPMENT OFFICER

Sold 1,109 shs ($17K)

Approx. gross sale proceeds $17K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	1,109	$15.00	$17K
Exercise	Restricted Stock Unit	1,774	$0.00	$0.00
Exercise	Common Stock	1,774	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 1,774 contracts (Direct); Common Stock — 224,173 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. F2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
3. F3. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did KalVista (KALV) report for Christopher Yea?

KalVista’s chief development officer reported RSU vesting and a tax sale. 1,774 restricted stock units converted into common shares, and 1,109 shares were sold at $15.00 each to cover tax withholding obligations through a pre-arranged “sell to cover” transaction.

Was the KalVista (KALV) insider stock sale by Christopher Yea discretionary?

The reported stock sale was not discretionary. Footnotes state the 1,109-share sale at $15.00 per share was executed solely to satisfy tax withholding obligations tied to RSU vesting under a “sell to cover” arrangement, rather than an elective open-market sale.

How many KalVista (KALV) RSUs vested for Christopher Yea in this filing?

1,774 restricted stock units vested and converted into common shares. Each RSU represents a right to receive one KalVista common share for no consideration. The award vests in 1/16th increments on each quarterly anniversary of the vesting commencement date, subject to continued service.

At what price were KalVista (KALV) shares sold in the reported insider transaction?

The reported KalVista share sale occurred at $15.00 per share. Christopher Yea sold 1,109 common shares in the open market to fund tax withholding obligations arising from the vesting and settlement of restricted stock units, according to the Form 4 footnotes.

What does each KalVista (KALV) restricted stock unit represent in this Form 4?

Each RSU equals one KalVista common share upon settlement. The filing states every restricted stock unit represents a contingent right to receive one share of the company’s common stock for no consideration, delivered as the award vests over scheduled quarterly installments.

How does the RSU vesting schedule work for KalVista (KALV) in this award?

The RSU award vests in equal quarterly installments. According to the footnotes, 1/16th of the total shares subject to the RSU vest on each quarterly anniversary of the vesting commencement date, conditioned on the reporting person’s continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 07:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yea Christopher

(Last) (First) (Middle)

C/O KALVISTA PHARMACEUTICALS, INC

200 CROSSING BOULEVARD

(Street)

FRAMINGHAM MA 01702

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KalVista Pharmaceuticals, Inc. [ KALV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF DEVELOPMENT OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		M		1,774	A	(1)	225,282	D
Common Stock	02/18/2026		S(2)		1,109	D	$15	224,173	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/17/2026		M			1,774	(3)	(3)	Common Stock	1,774	$0	1,774	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

3. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.

	/s/ Benjamin L. Palleiko, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.